Logo

SMLR

Semler Scientific, Inc.

SMLR

Semler Scientific, Inc. • NASDAQ
$21.72 ▲ 5.03% (+1.04)
Market Cap $329.27 M
52w High $81.56
52w Low $17.41
Dividend Yield 0%
P/E 4.19
Volume 155.45K
Outstanding Shares 15.16M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $7.491M ▼ $12.245M ▲ $16.902M ▼ 225.631% ▼ $1.14 ▼ $25.466M ▲
Q2-2025 $8.217M ▼ $9.531M ▼ $66.933M ▲ 814.567% ▲ $5.71 ▲ $-1.944M ▲
Q1-2025 $8.835M ▼ $38.999M ▲ $-64.702M ▼ -732.337% ▼ $-6.74 ▼ $-73.806M ▼
Q4-2024 $12.413M ▼ $7.769M ▲ $29.206M ▲ 235.286% ▲ $3.64 ▲ $3.641M ▼
Q3-2024 $13.512M $7.291M $5.609M 41.511% $0.8 $6.518M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $10.176M ▼ $596.677M ▲ $136.928M ▼ $459.749M ▲
Q2-2025 $13.482M ▲ $522.597M ▲ $139.188M ▲ $383.409M ▲
Q1-2025 $9.737M ▼ $293.445M ▲ $131.762M ▲ $161.683M ▼
Q4-2024 $14.919M ▲ $239.828M ▲ $9.078M ▲ $230.75M ▲
Q3-2024 $12.668M $92.194M $6.839M $85.355M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $16.902M ▼ $-32.95M ▼ $-47.779M ▲ $77.424M ▼ $-3.305M ▼ $-32.936M ▲
Q2-2025 $66.932M ▲ $514K ▲ $-149.668M ▼ $152.899M ▲ $3.745M ▲ $-149.154M ▼
Q1-2025 $-64.702M ▼ $-1.906M ▼ $-87.31M ▲ $90.135M ▼ $919K ▼ $-92.816M ▲
Q4-2024 $29.206M ▲ $7.427M ▲ $-120.999M ▼ $115.823M ▲ $2.251M ▲ $-113.841M ▼
Q3-2024 $5.609M $6.425M $-8.435M $1.247M $-763K $-2.01M

Five-Year Company Overview

Income Statement

Income Statement Over the past several years, Semler’s revenue has climbed steadily from a small base, and profitability has remained consistently positive. Gross margins are high, and operating profits have been stable, which is unusual for a small medical device company. The most recent year shows a sharp improvement in bottom‑line profit and earnings per share, suggesting strong operating leverage as the business scales. Overall, the income statement points to a focused, high‑margin niche business that is already solidly profitable, not a cash‑burning early‑stage story.

Balance Sheet

Balance Sheet The balance sheet is clean and conservative on the debt side: the company carries effectively no financial debt and is funded almost entirely by shareholder equity. Total assets have grown substantially in the most recent year, largely reflecting investment decisions rather than heavy physical infrastructure. Reported cash balances have moved around, and are relatively modest compared with total assets, in part because the company has shifted a significant portion of its treasury into Bitcoin. This creates a balance sheet that looks strong from a leverage standpoint but is meaningfully exposed to digital asset price swings.

Cash Flow

Cash Flow Semler generates steady, positive cash flow from its operations year after year. Free cash flow closely tracks operating cash flow because the business requires very little spending on equipment or long‑term assets, reflecting an asset‑light, software‑ and service‑oriented model. This consistency in cash generation provides financial flexibility and helps fund both growth initiatives and the Bitcoin strategy without resorting to borrowing. The main risk is not cash generation itself, but how that cash is subsequently deployed.

Competitive Edge

Competitive Edge Semler occupies a specialized niche in vascular diagnostics with QuantaFlo, a product that is faster, easier to use, and often more practical than traditional testing methods for peripheral artery disease. The company benefits from patented technology, a recurring license model rather than one‑time hardware sales, and growing clinical evidence that supports adoption. Integration with electronic health records and alignment with value‑based care trends further strengthen its positioning. However, the business is still relatively small and heavily concentrated around one flagship product, which leaves it exposed to competitive responses from larger device makers and to changes in medical guidelines or reimbursement.

Innovation and R&D

Innovation and R&D Innovation is centered on expanding the capabilities and indications of QuantaFlo and moving into broader cardiovascular areas. The company is seeking expanded regulatory clearance to use its technology beyond peripheral artery disease, which, if successful, could significantly widen its addressable market, though the timing is uncertain and depends on future regulatory decisions. The creation of CardioVanta to address heart failure and arrhythmia using a software‑as‑a‑service model shows intent to build a broader cardiac platform. At the same time, the choice to treat Bitcoin as a core treasury asset is a form of financial experimentation rather than traditional R&D, adding a layer of volatility and distraction risk alongside the more conventional medical technology roadmap.

Summary

Semler Scientific combines an unusual mix: a profitable, high‑margin medical device business built around a differentiated diagnostic tool, and an aggressive balance‑sheet strategy centered on Bitcoin. Financially, the core operations look sound: revenue has grown, margins are strong, cash flow is reliable, and there is no debt. Strategically, the company has carved out a defensible position in peripheral artery disease testing, with patents, recurring revenue, and clinical backing, and it is working to extend its technology into wider cardiovascular applications through QuantaFlo enhancements and the CardioVanta initiative. The main uncertainties lie in concentration on a single flagship product, dependence on future FDA and reimbursement outcomes, the challenges of competing with much larger medtech players, and the significant exposure to cryptocurrency volatility introduced by its treasury policy. Overall, it is a focused, profitable healthcare technology company whose risk profile is elevated by its unconventional financial strategy and by the need to successfully execute its next wave of medical innovations.

NEWS

October 28, 2025 · 5:05 PM UTC

Semler Scientific® to Release Third Quarter 2025 Financial Results

Read more

October 28, 2025 · 3:39 PM UTC

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2025 in Semler Scientific, Inc. Lawsuit – SMLR

Read more

October 28, 2025 · 2:49 PM UTC

Semler Scientific Deadline: SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

Read more

October 28, 2025 · 12:00 PM UTC

SMLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Semler Scientific, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Read more

October 28, 2025 · 10:45 AM UTC

SMLR Deadline Today: Rosen Law Firm Encourages Semler Scientific, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action First Filed by the Firm – SMLR

Read more